Folgen

  • What are the Hot Topics in Diabetes Research from a Journal's Perspective - Diabetologia

    What are the Hot Topics in Diabetes Research from a Journal's Perspective - Diabetologia
    Jan 9 2026
    In our first episode of 2026, Prof. Hindrik Mulder, Editor-in-Chief of Diabetologia, offers a journal’s-eye view of the most exciting and challenging developments in diabetes research today. Drawing on his unique overview of submissions from across the global research community, prof. Mulder discusses emerging breakthroughs such as hypoimmune stem cell-based therapies that are transforming from theoretical possibilities into scalable, off-the-shelf treatments for diabetes. Prof. Mulder discusses how these innovations could revolutionise diabetes care by overcoming the historical barriers of islet transplantation. We further explore Diabetologia's special 2025 issue on "Opportunities and Challenges in Diabetes," which tackles the critical issues of healthcare disparity, access, and equity. Prof. Mulder passionately addresses why diversity in research is essential to understanding disease heterogeneity and why the scientific community must continue advocating for inclusive research despite political headwinds. Learn about the journal's innovative approach to incorporating patient perspectives in research design, the appointment of a dedicated DEI editor, and the exciting launch of Metabologia - Diabetologia's new sister journal - covering the expanding landscape of metabolic disorders. This conversation reminds us that embracing complexity and acknowledging what we don't know is fundamental to advancing diabetes science.
    Mehr anzeigen Weniger anzeigen
    15 Min.
  • SURPASSing Therapeutic Challenges of Paediatric Type 2 Diabetes with Tirzepatide

    SURPASSing Therapeutic Challenges of Paediatric Type 2 Diabetes with Tirzepatide
    Dec 19 2025
    In this episode, Dr. Tamara Hannon (Indiana University Health) and Prof. Martin Wabitsch (Universtätsklinikum Ulm) unpack the findings of the SURPASS-PEDS trial - the first study to evaluate the dual GIP/GLP-1 receptor agonist tirzepatide in adolescents with type 2 diabetes. With youth-onset type 2 diabetes rising sharply across the US and Europe, and with young people experiencing faster beta-cell decline, more severe obesity, and greater socioeconomic burdens, the need for effective therapies has never been greater. They discuss why adolescent disease differs fundamentally from adult type 2 diabetes, why weight-loss expectations cannot be compared across age groups, and how tirzepatide not only reduces HbA1c but also halts the extreme weight-gain velocity commonly seen in this population. They also reflect on what early intervention could mean for long-term metabolic health, how guidelines may evolve, and how better treatment options could transform quality of life for young people living with type 2 diabetes. This conversation highlights why youth-onset type 2 diabetes is fundamentally different from adult disease, why weight loss behaves differently in children, and how early intervention could change the life course for young people at high risk of long-term complications.
    Mehr anzeigen Weniger anzeigen
    13 Min.
  • The EASD's First Clinical Guideline: Assessment and Management of Diabetes Distress

    The EASD's First Clinical Guideline: Assessment and Management of Diabetes Distress
    Dec 12 2025
    In this episode, EASD presents its inaugural clinical guideline on diabetes distress. Drawing on two years of multidisciplinary work, the guideline was developed by clinicians, methodologists, psychologists and people with lived experience. Prof. Jane Speight, Prof. Richard Holt and patient-advocate Michelle Law describe what diabetes distress is (the emotional burden tied to daily self-management) and why routine assessment and supportive care must become part of standard practice. The guideline sets out eight good practice statements to help clinicians normalise conversations about emotional wellbeing, plus graded recommendations for managing distress in adults with type 1 and type 2 diabetes. Psychological interventions are endorsed where evidence supports them, and clinic-level actions that clinicians can deliver without referral are highlighted. The panel also discusses evidence gaps, the need for practical tools and training, and how people living with diabetes can drive implementation by asking for these conversations in clinic. Join EASD TV to hear how this guideline aims to transform diabetes care by putting emotional wellbeing alongside clinical outcomes.
    Mehr anzeigen Weniger anzeigen
    16 Min.
  • Population Level Screening to Detect Early Stage Type 1 Diabetes

    Population Level Screening to Detect Early Stage Type 1 Diabetes
    Dec 5 2025
    In this episode, leading experts Anette Ziegler (Helmholtz Munich), Chantal Mathieu (KU Leuven & EASD President), and Anastasia Albanese-O’Neill (Breakthrough T1D) join EASD TV to discuss the emerging global consensus on screening for early-stage type 1 diabetes. They explore why population-wide screening is now considered both feasible and essential, how early detection can prevent DKA and enable access to disease-modifying therapies, and what the new guidance means for clinicians, health systems, and policymakers. From optimal screening ages and two-step testing strategies to implementation challenges, cost-effectiveness, and the promise of prevention, this conversation outlines one of the most significant shifts in type 1 diabetes care in decades.
    Mehr anzeigen Weniger anzeigen
    14 Min.
  • Results from the SOUL Trial: The Cardiologists' Perspective

    Results from the SOUL Trial: The Cardiologists' Perspective
    Nov 28 2025
    Last week we heard the diabetologist's perspective on cardiovascular outcomes. In this weeks episode, EASD TV continues its deep dive into major clinical trials with the cardiologist’s perspective. Cardiologist Dr. Matthew Cavender (University of North Carolina) joins Vivienne Parry to unpack the SOUL trial, a major cardiovascular outcomes study evaluating oral semaglutide in people with type 2 diabetes. The trial followed more than 8,000 high-risk participants and demonstrated a 14% reduction in major cardiovascular events, including cardiovascular death, myocardial infarction and stroke. Dr Cavender explains why having an effective oral GLP-1 receptor agonist is an important development for both diabetes and cardiovascular care, and what the findings mean for clinical practice, guideline implementation, and patient access. From cross-disciplinary teamwork to the future of evidence-based prescribing, this episode offers a clear look at how the SOUL trial is shaping modern treatment strategies.
    Mehr anzeigen Weniger anzeigen
    8 Min.
  • Results from the SOUL Trial: The Diabetologists' Perspective

    Results from the SOUL Trial: The Diabetologists' Perspective
    Nov 21 2025
    At the EASD 2024 Annual Meeting, the SOUL trial attracted significant attention as the first study to show cardiovascular risk reduction using an oral GLP-1 receptor agonist. In this episode, Dr Rodica Busui (Oregon Health & Science University-OHSU, Oregon, USA) explains the trial’s major outcomes, including a 14% reduction in major adverse cardiovascular events -matching results previously observed with injectable GLP-1 formulations. The discussion highlights the potential impact of an oral agent on clinical practice, including improved accessibility, suitability for older adults, and earlier use in the treatment pathway. Dr Busui also reviews new data on heart failure phenotypes, particularly HFpEF, and the growing need to address cardiometabolic multimorbidity in people with type 2 diabetes. Another key topic is the high proportion of participants using SGLT2 inhibitors in the trial. The reassuring safety data regarding combined therapy offers important guidance for clinicians prescribing contemporary cardiometabolic treatments. This episode provides a clear and timely overview of how oral GLP-1 therapies may influence the future of cardiovascular and diabetes care.
    Mehr anzeigen Weniger anzeigen
    9 Min.
  • ATTAIN-1 - Investigating Orforglipron for Obesity Management

    ATTAIN-1 - Investigating Orforglipron for Obesity Management
    Nov 14 2025
    In this episode, Dr. Sean Wharton (University of Toronto and Wharton Medical Clinic, Canada) and Dr. Nasreen Alfaris (King Fahad Medical City, Riyadh, Saudi Arabia) join host Vivienne Parry to discuss the groundbreaking ATTAIN trial, presented at the EASD 2025 Annual Meeting in Vienna. The trial tested Orforglipron, the first oral small molecule GLP-1 receptor agonist, showing promising results in weight reduction and cardiometabolic improvements among people living with overweight or obesity. Beyond the data, the discussion explores what makes Orforglipron different, from its potential to expand access and affordability, to its implications for type 2 diabetes prevention. With obesity now the most common chronic disease worldwide, could this be a pivotal step toward truly scalable care?
    Mehr anzeigen Weniger anzeigen
    12 Min.
  • Pancreas Development: A Key to Discover Unexpected Treatments of Diabetes

    Pancreas Development: A Key to Discover Unexpected Treatments of Diabetes
    Nov 7 2025
    What does the future hold for beta cell biology and diabetes treatment? Join Prof. Raphaël Scharfmann (INSERM), recipient of the 2025 Albert Renold Prize, as he explores how developmental biology is unlocking new ways to generate functional beta cells - an important step toward curing diabetes. In this inspiring interview from the EASD 2025 Annual Meeting in Vienna, Prof. Scharfmann discusses the progress in stem cell-derived beta cell generation, the collaboration driving translational research, and the next big challenge, counting beta cells in the living human pancreas. Discover how decades of research are shaping the next frontier in diabetes science and what it means for future therapies.
    Mehr anzeigen Weniger anzeigen
    5 Min.